Mineralys Therapeutics Inc. (MLYS) News
Filter MLYS News Items
MLYS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MLYS News Highlights
- MLYS's 30 day story count now stands at 2.
- Over the past 24 days, the trend for MLYS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about MLYS are DEC.
Latest MLYS News From Around the Web
Below are the latest news stories about MINERALYS THERAPEUTICS INC that investors may wish to consider to help them evaluate MLYS as an investment opportunity.
Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension– Topline data from confirmatory Launch-HTN trial expected in 2H 2025 – – Topline data from ongoing Advance-HTN pivotal trial expected in 2H 2024 – RADNOR, Pa., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that the first subject has been dosed in the Launch-HT |
Positive Signs As Multiple Insiders Buy Mineralys Therapeutics StockWhen a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase... |
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q3 2023 Earnings Call TranscriptMineralys Therapeutics, Inc. (NASDAQ:MLYS) Q3 2023 Earnings Call Transcript November 12, 2023 Operator: Good afternoon, ladies and gentlemen, and welcome to the Mineralys Therapeutics Third Quarter 2023 Conference Call. [Operator Instructions]. It is now my pleasure to introduce your host, Dan Ferry, of LifeSci Advisors. Please go ahead. Dan Ferry: Thank you, operator. Good afternoon, […] |
Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023– New analysis on serum leptin levels among patients in the Target-HTN Phase 2 trial adds to emerging evidence of positive feedback loop linking obesity, leptin and aldosterone – – Excess aldosterone in patients with visceral obesity defines a unique hypertensive endotype with potential for an enhanced response to aldosterone-targeted therapy with lorundrostat – – Early identification and intervention with lorundrostat may result in improved clinical outcomes for obese patients with uncontrolled |
Mineralys Therapeutics to Participate in Three Upcoming ConferencesRADNOR, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that members of the senior management will be participating in the Stifel Healthcare Conference being held in New York on November 14-15, the Jefferies London Healthcare Conference being held in London |
Mineralys Therapeutics Inc (MLYS) Reports Q3 2023 Financials; R&D Expenses Rise Amid ...Key Financial and Clinical Progress as Company Prepares for Phase 3 Trial |
Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update– On track to initiate planned Phase 3 pivotal Launch-HTN trial of lorundrostat to treat patients with uncontrolled or resistant hypertension in 2H 2023 – – Expect to initiate planned Phase 2 Explore-CKD trial of lorundrostat alone and in combination with SGLT2 inhibitor to treat hypertensive patients with chronic kidney disease (CKD) in 2H 2023 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage |
Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting– Analysis further supports obesity-associated dysregulated aldosterone as an endotype predictive of enhanced response to lorundrostat treatment in patients with uncontrolled or treatment-resistant hypertension – –Endotype identification from Target-HTN may represent a shift towards targeted, precision-directed therapy for hypertension management in future treatment paradigm – – Ongoing Advance-HTN trial, first of two pivotal studies, will further characterize hypertensive endotype for enhanced |
Mineralys Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on Tuesday, November 7, 2023RADNOR, Pa., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced it will report its financial results from the third quarter ended September 30, 2023, after the financial markets close on Tuesday, November 7, 2023. Tuesday, November 7th @ 4:30 p.m. ET Domestic: 1-888 |
We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although... |